Ge Healthcare Drug Patent Portfolio
Ge Healthcare owns 3 orange book drugs protected by 8 US patents Given below is the list of Ge Healthcare's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8916131 | Radiopharmaceutical composition | 16 Sep, 2028 | Active |
| US7270800 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | 03 Sep, 2025 | Active |
| US8236282 | Benzothiazole derivative compounds, compositions and uses | 21 May, 2024 | Expired |
| US7351401 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | 24 Jan, 2023 | Expired |
| US8691185 | Benzothiazole derivative compounds, compositions and uses | 24 Jan, 2023 | Expired |
| US6723303 | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane | 20 Apr, 2021 | Expired |
| US5560903 | Method of enhancing paramagnetism in chelates for MRI | 01 Oct, 2013 | Expired |
| US5529766 | Contrast agents | 25 Jun, 2013 | Expired |
Latest Legal Activities on Ge Healthcare's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ge Healthcare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2024 | US8236282 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2022 | US8916131 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Sep, 2021 | US8691185 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2020 | US8236282 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2019 | US7351401 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Mar, 2019 | US7270800 |
| Post Issue Communication - Certificate of Correction | 27 Nov, 2018 | US7270800 |
| Post Issue Communication - Certificate of Correction | 14 Nov, 2018 | US8236282 |
| Post Issue Communication - Certificate of Correction | 07 Nov, 2018 | US8691185 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Jun, 2018 | US8916131 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Sep, 2017 | US8691185 |
|
Patent Term Extension Certificate
Critical
| 21 Mar, 2017 | US7270800 |
| Notice of Final Determination -Eligible | 07 Dec, 2016 | US7270800 |
|
FDA Final Eligibility Letter
Critical
| 29 Jul, 2016 | US7270800 |
| transaction for FDA Determination of Regulatory Review Period | 15 Dec, 2015 | US7270800 |
Ge Healthcare's Drug Patent Litigations
Ge Healthcare's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 28, 2000, against patent number US6723303. The petitioner , challenged the validity of this patent, with QUAY as the respondent. Click below to track the latest information on how companies are challenging Ge Healthcare's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6723303 | March, 2000 |
Decision
(30 Oct, 2003)
| QUAY | |
Ge Healthcare's Family Patents
Ge Healthcare Drug List
Given below is the complete list of Ge Healthcare's drugs and the patents protecting them.
1. Omniscan
Omniscan is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5560903 | Method of enhancing paramagnetism in chelates for MRI |
01 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omniscan's drug page
2. Optison
Optison is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6723303 | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
20 Apr, 2021
(3 years ago)
| Expired |
| US5529766 | Contrast agents |
25 Jun, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Optison's drug page
3. Vizamyl
Vizamyl is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8916131 | Radiopharmaceutical composition |
16 Sep, 2028
(3 years from now)
| Active |
| US7270800 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
03 Sep, 2025
(10 months from now)
| Active |
| US8236282 | Benzothiazole derivative compounds, compositions and uses |
21 May, 2024
(4 months ago)
| Expired |
| US7351401 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition |
24 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US8691185 | Benzothiazole derivative compounds, compositions and uses |
24 Jan, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vizamyl's drug page